Abstract
Cholinesterase inhibition is one of the major strategies to develop better quality anti-Alzheimer’s drug, while inhibition of glycation pathway is a useful therapeutic strategy to treat diabetic complications. This study was designed to evaluate the anti-acetylcholinesterase, anti-butyrylcholinesterase and anti-glycation activities of 8 secondary metabolites namely, RS-8, RS-22C (arborinine), CL-1 (betulinic acid), CL-2 (ursolic acid), CCL-1 (cajaninstilbene acid), CP-1 (beta-sitosterol), HS-1 (anhydrofusarubin) and HS-2 (methylether of fusarubin). It was found that RS-8 and arborinine showed promising activity in inhibiting acetylcholinesterase with IC50 values of 24.40 ± 0.39 and 13.14 ± 0.07, respectively. Anhydrofusarubin and methyl ether of fusarubin exhibited moderate activities with IC50 values of 47.82 ± 0.54 and 44.58 ± 0.8. Arborinine and cajaninstilbene acid potentially inhibited butyrylcholinesterase with IC50 values of 26.34 ± 0.31 and 25.82 ± 0.34, respectively, but other metabolites did not show such inhibitory activities. Inhibition of glycation process was evaluated by bovine serum albumin assay but none of the metabolites significantly inhibited the glycation pathway.
 Dhaka Univ. J. Pharm. Sci. 18(1): 31-38, 2019 (June)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Dhaka University Journal of Pharmaceutical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
